US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.89
▼-1.02%
TSLA
$378.69
▲+2.18%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
META
$741.90
▲+1.90%
INTC
$116.19
▼-2.63%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.89
▼-1.02%
TSLA
$378.69
▲+2.18%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
META
$741.90
▲+1.90%
INTC
$116.19
▼-2.63%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Harpoon Therapeutics
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
June 27, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
April 18, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
April 17, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
April 10, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
March 27, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
March 14, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
December 11, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
December 05, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
November 03, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
October 04, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Tickers
HARP
